SyntheticGestalt
SyntheticGestalt is a Tokyo-based AI company founded in 2018 that builds molecule-specialized foundation AI models (SG4D10B trained on 10 billion compounds) for pharmaceutical drug discovery, enzyme discovery, and sustainable chemistry, serving enterprise customers via licensing and joint development.
- Company typePrivate
- Founded2018
- HeadquartersTokyo, Japan
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What SyntheticGestalt does
SyntheticGestalt KK is a Tokyo-based AI company founded in 2018 that develops molecule-specialized foundation AI models for drug discovery, enzyme discovery, and sustainable chemistry applications. The company's core technology is built around Geometric Deep Learning techniques applied to 1D, 2D, 3D, and 4D molecular structures (the last accounting for conformational changes), enabling accurate prediction of small molecule-protein interactions. Its flagship model, SG4D10B, is trained on 10 billion compound data points and has achieved world #1 rankings on the Therapeutics Data Commons standard evaluation framework for toxicity, permeability, and stability benchmarks. A compact version, SG4D100M, is distributed free of charge through Google Cloud Marketplace and AWS Marketplace to drive adoption among the broader research community.
The company operates two principal AI product systems—a Drug Discovery System (lead activity, drug-likeness, and novel compound generation across tens of billions of compound space) and an Enzyme Discovery System (applied to plastic-degrading enzymes, CO2-fixing enzymes, and pharmaceutical production enzymes)—complemented by joint development services that integrate clients' proprietary data with SyntheticGestalt's foundation models. Revenue is generated primarily through enterprise licensing and deployment agreements with pharmaceutical and industrial partners (e.g., Taiho Pharmaceutical, Shionogi, Kyowa Hakko Bio, Yokogawa Electric, Asahi Quality and Innovations), professional services for joint AI development, and a freemium distribution layer via cloud marketplaces. The company has raised approximately $17 million in total funding as of mid-2026, with a Series B in progress, and participates in multiple Japanese government-backed programs including GENIAC (Phases 2 and 3), LINK-J UNIKORN, and the J-StarX AI Medical Course for US market entry.
SyntheticGestalt firmographics
Firmographics- Name
- SyntheticGestalt
- Legal name
- SyntheticGestalt KK
- Website
- https://syntheticgestalt.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SyntheticGestalt is a Tokyo-based AI company founded in 2018 that builds molecule-specialized foundation AI models (SG4D10B trained on 10 billion compounds) for pharmaceutical drug discovery, enzyme discovery, and sustainable chemistry, serving enterprise customers via licensing and joint development.
- Ownership category
- akta.pro rank
SyntheticGestalt industry classification
Industry- Product category
- Drug Discovery Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
Keywords
Where SyntheticGestalt is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices1 record
Markets served
SyntheticGestalt business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Enterprise AI Licensing and Deployment: B2B licensing of molecular foundation AI models (SG4D10B) to pharmaceutical companies through technical validation projects and long-term deployment agreements. Revenue generated from collaborative development, model access, and customization services with enterprise clients like Taiho Pharmaceutical.
- Cloud Marketplace Distribution: Free distribution of compact SG4D100M model on Google Cloud Marketplace and AWS Marketplace drives adoption and brand reach, potentially leading to enterprise upsell opportunities.
- Joint Development Services: Joint development of custom AI solutions powered by proprietary data for pharmaceutical, enzyme, and materials companies. Tailored approach transforms client data into competitive advantages through collaborative R&D partnerships.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Others | SG4D100M Compact Model - Free Tier |
| Subscription | Annual | Enterprise Deployment - Custom Pricing |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
SyntheticGestalt product offering
Product offeringCore offering
SyntheticGestalt develops and licenses molecule-specialized foundation AI models (SG4D10B and SG4D100M) that accelerate drug discovery and sustainable chemistry applications. The company's technology combines proprietary Geometric Deep Learning with 1D-4D molecular structural data to predict protein interactions, generate novel compounds, screen enzymes, and optimize leads for pharmaceutical, biomanufacturing, and chemical materials customers. Products are delivered through enterprise licensing agreements, joint development partnerships, and free cloud-marketplace distribution of the compact model.
Product overview
SyntheticGestalt offers a portfolio of molecule-specialized AI products centered on its foundation AI models (SG4D10B, SG4D100M) that form the core technology platform. The company's offerings span two main AI systems: the Drug Discovery System (for small molecule pharmaceutical research) and the Enzyme Discovery System (for biomanufacturing applications). These are complemented by collaborative services for joint AI development and joint substance discovery. The foundation models trained on billions of molecular data points serve as the underlying technology that powers all products and services, with the compact SG4D100M model providing accessible distribution through cloud marketplaces. The company also enables partner-specific solutions such as the Cysteinomix platform validation with Taiho Pharmaceutical.
Differentiator
Problem solved
Functional benefit
Products and services
- SG4D10B - Molecule-Specialized Foundation AI Model World's largest molecule-specialized foundation AI model trained on 10 billion compound data points; achieves world #1 rankings in three critical drug discovery benchmarks (toxicity, permeability, stability) on the Therapeutics Data Commons standard evaluation framework. Deployed through enterprise licensing agreements with pharmaceutical partners including Taiho Pharmaceutical.
- SG4D100M - Compact Molecule-Specialized Foundation AI Model Compact version of the molecule-specialized foundation AI model, available for free on Google Cloud Marketplace and AWS Marketplace to enable broader researcher and pharmaceutical-company access to the company's molecular AI technology for drug discovery and compound exploration.
- Drug Discovery System AI-driven system that accelerates the drug discovery process by combining foundation AI models with predictive models of lead activity, drug-likeness, and novel compound generation. Selects optimal candidates from tens of billions of compound spaces for pharmaceutical customers.
- Enzyme Discovery System AI-powered enzyme discovery system that finds desired enzyme functions from large amounts of genetic sequence information. Applied to plastic-degrading enzymes, carbon dioxide-fixing enzymes, and pharmaceutical production enzymes for biomanufacturing customers.
- Joint Development of AI for Discovery of New Substances Service offering that integrates SyntheticGestalt's foundation AI with clients' existing data and search infrastructure to create tailored AI solutions, transforming proprietary information into competitive advantages through collaborative R&D partnerships with pharmaceutical, enzyme, and materials companies.
- Joint Search for Novel Substances Using AI Collaborative discovery service using proprietary AI technology to uncover valuable new compounds across pharmaceuticals and innovative materials, working alongside client R&D teams to enhance capabilities and drive scientific breakthroughs.
- iPS Cell Differentiation Target Discovery AI-powered research service that discovers new gene differentiation targets for liver regeneration from iPS cells by evaluating approximately 10 million gene combinations to significantly accelerate life sciences research.
Quantifiable outcome
- Computational acceleration of 30,000 to 100,000 times for drug discovery and chemical development
- +2 more outcomes
Companies that use SyntheticGestalt
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
SyntheticGestalt technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability6 records
Feature6 records
SyntheticGestalt partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and moderate.
- Taiho PharmaceuticalcoreTechnical validation collaboration using SG4D10B molecular foundation AI model to enhance Taiho's Cysteinomix drug discovery platform. Aims to improve prediction accuracy of molecular profiles to increase success rate of discovering covalent drugs for historically undruggable targets. Taiho's Cysteinomix platform has track record of creating an agent approved in Japan, US, and Europe with multiple agents in clinical development.
- EnaminecoreStrategic partnership with Enamine to advance AI models for drug discovery. The collaboration enables SyntheticGestalt's AI to efficiently search Enamine's large libraries of tens of billions of compounds, suggesting candidate compounds for experiments with unprecedented speed and efficiency.
- Asahi Quality and InnovationsmoderateJoint research on AI-powered PET bottle recycling technology called 'Bio-Recycling' to develop enzymatic decomposition methods for PET recycling at lower temperatures, discovering highly efficient PETase enzymes for scalable and sustainable PET recycling.
- Tokyo University of Science (Science Tokyo)moderateAcademic collaboration in joint research on next-generation AI-driven PET bottle recycling technology, contributing scientific expertise to the bio-recycling project.
- Shionogi & Co., Ltd.coreCollaboration with Shionogi and Hokkaido University to identify new anti-coronavirus drug candidate compounds using SyntheticGestalt's AI drug discovery technology.
- Hokkaido UniversitycoreAcademic partnership with Shionogi for anti-coronavirus drug candidate discovery using AI technology, combining university research capabilities with company AI expertise.
- D. Western Therapeutics Institute (DWTI)moderateCollaboration to co-discover novel, multi-targeted kinase inhibitors for treatment of inflammation and central nervous system diseases, applying AI to DWTI's therapeutic focus areas.
- Kyowa Hakko Bio Co., Ltd.moderateEnzyme screening partnership using company's enzyme discovery system to discover new enzymes applicable to pharmaceutical production with activity levels previously considered difficult to achieve, verified through wet experiments.
- Yokogawa Electric CorporationmoderateResearch and development collaboration to create cell line identifier incorporating time information for cell evaluation technology, achieving solutions difficult with conventional methods.
- METI/NEDO (GENIAC Project)coreSelected for GENIAC (Generative AI Accelerator Challenge) - Japanese Ministry of Economy, Trade and Industry (METI) and NEDO project. Building chemical AI database 10x larger than current global standard with 100,000-200,000 entries. Achievement of computational acceleration of 30,000-100,000x for drug discovery.
- LINK-J (UNIKORN Program)moderateSelected for LINK-J's UNIKORN Phase 2 program, a startup support initiative focused on life science innovation, providing institutional backing and visibility within Japan's life sciences ecosystem.
- METI/JETRO (J-StarX AI Medical Course)coreSelected for J-StarX AI Medical Course - competitive public-private initiative supporting Japanese healthtech startups' entry into US market. Maximum 12 companies receive specialized US healthcare ecosystem training, Mayo Clinic visits, and networking opportunities to establish US business foundation.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
SyntheticGestalt competitors and assessment
Company assessmentMarket position
Strengths4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
SyntheticGestalt social profiles
Digital presenceSyntheticGestalt financial estimates
Financial estimateRevenue estimate
Valuation estimate
SyntheticGestalt leadership team
Management profileNumber of profiles
Profiles3 records
SyntheticGestalt funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SyntheticGestalt M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SyntheticGestalt
What does SyntheticGestalt do?
SyntheticGestalt develops and licenses molecule-specialized foundation AI models (SG4D10B and SG4D100M) that accelerate drug discovery and sustainable chemistry applications. The company's technology combines proprietary Geometric Deep Learning with 1D-4D molecular structural data to predict protein interactions, generate novel compounds, screen enzymes, and optimize leads for pharmaceutical, biomanufacturing, and chemical materials customers. Products are delivered through enterprise licensing agreements, joint development partnerships, and free cloud-marketplace distribution of the compact model.
Is SyntheticGestalt a public or private company?
SyntheticGestalt is a private company. It is classified as venture growth investor backed and is currently operating.
When was SyntheticGestalt founded?
SyntheticGestalt was founded in 2018. It employs 11 to 50 people.
Where is SyntheticGestalt based?
SyntheticGestalt is headquartered in Tokyo, Japan, in the Asia region.
How does SyntheticGestalt make money?
Three revenue lines are on record. Enterprise AI Licensing and Deployment is the primary driver. The others are cloud Marketplace Distribution and joint Development Services.
Does SyntheticGestalt have an API?
No public API is recorded for SyntheticGestalt.
What industry is SyntheticGestalt in?
SyntheticGestalt's product category is Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.